Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | MAT2A | P31153 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | SNCA | P37840 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271216 | 0.93 | KIF11 (0.39) | KIF11KCNH2MAOBMAOAIDH1 | |
| SCHEMBL3268480 | 0.90 | KCNH2 (0.37) | KIF11KCNH2MAOBMAOAIDH1 | |
| SCHEMBL3273254 | 0.89 | MAOB (0.43) | KIF11KCNH2MAOBMAOA | |
| SCHEMBL3271196 | 0.88 | KIF11 (0.58) | KIF11KCNH2 | |
| SCHEMBL3269731 | 0.87 | KIF11 (0.45) | KIF11KCNH2MAOBMAOA | |
| SCHEMBL3269903 | 0.87 | KIF11 (0.45) | KIF11KCNH2MAOBMAOA | |
| SCHEMBL3269852 | 0.86 | KIF11 (0.48) | KIF11KCNH2MAOBCNR1CNR2 | |
| SCHEMBL3269665 | 0.85 | VKORC1 (0.39) | KIF11KCNH2MAOBCNR1CNR2 | |
| SCHEMBL10246484 | 0.83 | KIF11 (0.45) | KIF11KCNH2MAOBMAT2ACNR1 | |
| SCHEMBL10192144 | 0.83 | KIF11 (0.45) | KIF11KCNH2MAOBMAT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | claimed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007067752-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | CYTOKINETICS, INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20100105767-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7629477-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | disclosed |
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1956908-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | Cytokinetics, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007067752-A2 | CERTAIN COMPOSITIONS AND METHODS OF TREATMENT | CYTOKINETICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | TOP2A, TOP2B, TOP1 | KIF11 20/4885KCNH2 955/4885MAOB 3682/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885MAOB 2109/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885MAOB 2109/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885MAOB 2109/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885MAOB 2109/4885 |
| US-20100105767-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885MAOB 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.